Eli Lilly and Company posted a surge in fourth-quarter revenues on Thursday, fuelled by strong demand for its blockbuster diabetes and weight-loss drugs.
Major Wall Street indexes saw slight gains on Thursday as strong earnings reports from companies like Eli Lilly, Tapestry, ...
The S&P 500 and Nasdaq ended higher with boosts from gains in Nvidia and Eli Lilly, while the Dow dipped slightly after a ...
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...
Sarah O’Keeffe recounts her fulfilling career path with Eli Lilly from employee to Senior Vice President, Product Research ...
The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug ...
Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...
Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...
Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...
Lupin Ltd (BOM:500257) reports its highest EBITDA margin in five years, driven by strong performance across key markets and strategic acquisitions.
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback